Spire Healthcare Group (LON:SPI) Sets New 12-Month High on Analyst Upgrade

Spire Healthcare Group plc (LON:SPI)’s stock price hit a new 52-week high on Thursday after Berenberg Bank raised their price target on the stock from GBX 286 to GBX 300. Berenberg Bank currently has a buy rating on the stock. Spire Healthcare Group traded as high as GBX 252.50 ($3.14) and last traded at GBX 248 ($3.09), with a volume of 3522562 shares trading hands. The stock had previously closed at GBX 238.50 ($2.97).

Separately, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a GBX 295 ($3.67) price objective on shares of Spire Healthcare Group in a research note on Monday, February 26th.

Spire Healthcare Group Price Performance

The company has a debt-to-equity ratio of 170.37, a current ratio of 0.69 and a quick ratio of 0.74. The company’s 50 day moving average is GBX 237.41 and its 200 day moving average is GBX 228.84. The stock has a market cap of £1.00 billion, a price-to-earnings ratio of 3,514.29, a PEG ratio of 1.06 and a beta of 0.99.

Spire Healthcare Group Increases Dividend

The business also recently disclosed a dividend, which will be paid on Friday, June 21st. Investors of record on Thursday, May 23rd will be paid a GBX 2.10 ($0.03) dividend. This is a boost from Spire Healthcare Group’s previous dividend of $0.50. The ex-dividend date of this dividend is Thursday, May 23rd. This represents a dividend yield of 0.89%. Spire Healthcare Group’s dividend payout ratio (DPR) is 4,285.71%.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.